ArticleGut2017

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.

Naoki Ikenaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.